{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["atezolizumab","abiraterone","prednisone"],["atezolizumab","enzalutamide"]],"indication":"newly diagnosed hormone-sensitive metastatic prostate cancer","name":"SAABR","nct_id":"NCT04262154","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=saabr-nct04262154. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants will have untreated metastatic (M1a/b/c) hormone-sensitive prostate cancer documented by positive bone scan or metastatic lesion on CT or MRI; untreated is defined as having never received surgical, radiotherapeutic, or systemic therapy for their prostate cancer.Group 1 and 2. The first 20 patients enrolled will be in Group 1 and the remaining patients (and those who are already on a GnRH analog) will be assigned to Group 2. All study participants will receive treatment with atezolizumab, abiraterone acetate, prednisone, GnRH analog, and SBRT, at the same doses.","label":"Metastatic Prostate Cancer","type":"EXPERIMENTAL"}],"collaborators":["Genentech, Inc.","Stand Up To Cancer"],"completion_date":{"date":"2027-09","type":"ESTIMATED"},"conditions":["Metastatic Prostate Cancer"],"enrollment":{"count":28,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Atezolizumab","otherNames":[],"type":"DRUG"},{"name":"Abiraterone","otherNames":[],"type":"DRUG"},{"name":"Prednisone","otherNames":[],"type":"DRUG"},{"name":"GnRH analog","otherNames":[],"type":"DRUG"},{"name":"Stereotactic Body Radiotherapy (SBRT)","otherNames":[],"type":"RADIATION"},{"name":"Enzalutamide","otherNames":[],"type":"DRUG"},{"name":"Follow up","otherNames":[],"type":"OTHER"}],"last_update":"2026-10-22","lead_sponsor":"Memorial Sloan Kettering Cancer Center","official_title":"SAABR: Single Arm Phase II Study of AR Targeted Therapy + Atezolizumab + GnRH Analog and Stereotactic Body Radiotherapy (SBRT) to the Prostate in Men With Newly Diagnosed Hormone-sensitive Metastatic Prostate Cancer","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2025-07-07","type":"ACTUAL"},"primary_outcomes":[{"measure":"Failure-free Rate at 2 Years","timeFrame":"2 years"}],"references":[],"start_date":{"date":"2020-03-03","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer","url":"https://clinicaltrials.gov/study/NCT04262154"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/saabr-nct04262154"}